Novaken Pharm key facts
as of Oct 2026- Manufacturer of medicines and health products intended to control drug release, sustained release and targeted drug release.
- Novaken Pharm is valued at approximately $215.1M as of Oct 2026 (last reported valuation).
- It has raised $39.1M; the latest was IPO in Dec 2025.
- Notable investors include Zhuhai Gree Financial Investment, ZJVC Venture Capital, Taiyou Fund, Lianyungang Jinhai Venture Capital, Guangzhou Guangyao Capital — 9 tracked in total.
- Status: In IPO Registration.
Novaken Pharm's last reported valuation, Nov 2025. Nothing priced has surfaced since.
- ·Watch Novaken Pharm: the Monday email on marks, rounds and moves
Novaken Pharm funding rounds
No funding rounds for Novaken Pharm are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Novaken Pharm valuation
Novaken Pharm's last reported valuation was $215 million in Nov 2025. No priced round, secondary trade or fund mark has surfaced since.
Novaken Pharm investors
9 investors are on record for Novaken Pharm, including Zhuhai Gree Financial Investment, ZJVC Venture Capital, Taiyou Fund and Lianyungang Jinhai Venture Capital.
About Novaken Pharm
Manufacturer of medicines and health products intended to control drug release, sustained release and targeted drug release. The company's pharmaceutical preparations focus on new drug formulations and drug delivery systems, enabling patient to recover from disease.
- Sector
- Business Products and Services (B2B)
- HQ
- Guangzhou, China
- Founded
- 2007
- Employees
- 185
- Website
- novaken.cn/
- Ownership
- In IPO Registration
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.